Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tool helps patients and therapists make better choices for leg pain

NCT ID NCT05232474

Knowledge-focused Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a tool called KomPas+ that helps therapists and patients with leg pain from blocked arteries (intermittent claudication) make shared decisions about treatment. Over 2,200 participants used the tool to see if it improved walking distance and quality of life. The goal was to see if adding personalized forecasts to standard care leads to better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2,271 people

The number who actually took part.

Started

Oct 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Primary objective: \- All therapists affiliated with Chronisch Zorgnet and specialized in the treatment of people with intermittent claudication are eligible to participate. Besides, all patients referred to a Chronisch Zorgnet therapist with intermittent claudication specialty are eligible to participate. Inclusion Criteria Secondary objective: * Provides written informed consent (both therapist and patients) * Therapists should have finished two KomPas (control group) or KomPas+ (experimental group) e-learnings * Therapists should have applied KomPas (control group) or KomPas+ (experimental group) to at least one patient with intermittent claudication Inclusion Criteria Third objective: \- All therapists affiliated with Chronisch Zorgnet and specialized in the treatment of people with intermittent claudication who are included in the experimental group are eligible to participate. Exclusion Criteria: * Not applicable due to the "real world" setting of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intermittent claudication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

intermittent vascular claudication peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intermittent claudication Peripheral arterial disease

Contacts and locations

Locations

  • IQ healthcare, Radboudumc

    Nijmegen, 6525 EP, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.